RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 uM.
CAS：1290541-46-6
分子式：C22H17N3O
分子量：339.39
纯度：98%
存储：Store at -20°C

Background:

RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 uM.

RAD51 Inhibitor B02 specifically inhibits human RAD51 (IC50=27.4 uM), but not its E. coli homologue RecA (IC50>250 uM)[1]. The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231[2].

B02 significantly enhances the therapeutic effect of cisplatin on tumor cells in vivo. B02 is tolerated by mice at doses up to 50 mg/kg without obvious body weight loss. No inhibition of tumor growth is observed on mice solely treated by B02. Mice treated with 4 mg/kg cisplatin, however, shows a 33% inhibition of tumor growth. Finally, mice treated with 50 mg/kg B02 and 4 mg/kg cisplatin shows a 66% inhibition of tumor growth[2].

参考文献:
[1]. Huang F, et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011 Jun 17;6(6):628-35.
[2]. Huang F, et al. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One. 2014 Jun 27;9(6):e100993.